We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+8.9%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$1.38B
AUM Growth
+$125M
Cap. Flow
+$100M
Cap. Flow %
7.26%
Top 10 Hldgs %
41.14%
Holding
237
New
73
Increased
38
Reduced
39
Closed
63

Top Buys

Rank Stock Value
1
MIST icon
Milestone Pharmaceuticals
MIST
+$12.5M
2
ETNB
89bio
ETNB
+$10.8M
3
IMTX icon
Immatics
IMTX
+$6.72M
4
BMY icon
Bristol-Myers Squibb
BMY
+$6.02M
5
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$5.91M

Top Sells

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$15.7M
2
BTAI icon
BioXcel Therapeutics
BTAI
+$12.5M
3
KURA icon
Kura Oncology
KURA
+$10.1M
4
STSA
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
+$9.46M
5
ZGNX
Zogenix, Inc.
ZGNX
+$7.96M

Sector Composition

Rank Sector Weight
1 Healthcare 25.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYTK icon
126
Cytokinetics
CYTK
$10.5B
$1.19M 0.09%
+55,000
New +$1.29M
DCTH icon
127
Delcath Systems
DCTH
$422M
$1.09M 0.08%
94,000
– –
GOSS icon
128
CALL
Gossamer Bio
GOSS
$82.9M
$1.01M 0.07%
+81,300
New +$1.08M
CLDX icon
129
CALL
Celldex Therapeutics
CLDX
$2.99B
$946K 0.07%
63,800
-210,700
-77% -$2.47M
BIIB icon
130
Biogen
BIIB
$30B
$852K 0.06%
3,000
+2,205
+277% +$615K
SIOX
131
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$820K 0.06%
177,684
-11,200
-6% -$37K
PCVX icon
132
Vaxcyte
PCVX
$7.81B
$796K 0.06%
16,110
-123,703
-88% -$4.93M
CRNX icon
133
Crinetics Pharmaceuticals
CRNX
$8.84B
$784K 0.06%
+50,000
New +$764K
ANAB icon
134
AnaptysBio
ANAB
$1.58B
$738K 0.05%
50,000
+45,419
+991% +$819K
TVRD
135
CALL
Tvardi Therapeutics
TVRD
$19.7M
$738K 0.05%
1,611
+1,067
+196% +$620K
MREO
136
Mereo BioPharma
MREO
$54.7M
$688K 0.05%
+1,196,308
New +$3.5M
IFRX icon
137
InflaRx
IFRX
$250M
$637K 0.05%
149,750
-2,850
-2% -$13.1K
DBVT
138
DBV Technologies
DBVT
$799M
$596K 0.04%
16,473
– –
APLS
139
DELISTED
Apellis Pharmaceuticals
APLS
$565K 0.04%
18,726
+16,600
+781% +$496K
PBYI icon
140
Puma Biotechnology
PBYI
$404M
$554K 0.04%
54,901
– –
AL
141
PUT
DELISTED
Air Lease Corp
AL
$518K 0.04%
+17,600
New +$519K
RAPT
142
PUT
DELISTED
RAPT Therapeutics
RAPT
$503K 0.04%
+1,950
New +$433K
ADMA icon
143
ADMA Biologics
ADMA
$1.96B
$478K 0.03%
200,000
-178,574
-47% -$490K
AVTX icon
144
Avalo Therapeutics
AVTX
$965M
$460K 0.03%
70
-70
-50% -$526K
CRBP icon
145
CALL
Corbus Pharmaceuticals
CRBP
$166M
$397K 0.03%
7,337
-25,996
-78% -$4.71M
ARNA
146
DELISTED
Arena Pharmaceuticals Inc
ARNA
$373K 0.03%
5,000
– –
ABUS icon
147
Arbutus Biopharma
ABUS
$857M
$360K 0.03%
+115,000
New +$350K
EPZM
148
DELISTED
Epizyme, Inc
EPZM
$347K 0.03%
+29,080
New +$390K
NVAX icon
149
Novavax
NVAX
$1.2B
$286K 0.02%
+2,636
New +$321K
BXRX
150
DELISTED
Baudax Bio, Inc. Common Stock
BXRX
$277K 0.02%
71
– –
4 5
6
7 8

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q3 2020 Portfolio in Review

As of Q3 2020, Ikarian Capital held 237 positions worth $1.38B, up 10% from $1.26B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Ikarian Capital deployed $100M of net new capital in Q3 2020, opening 73 new positions and adding to 38 existing holdings. Its largest new stake was Milestone Pharmaceuticals: 1,743,545 shares worth $12.8M.

By sector, the portfolio is most concentrated in Healthcare at 25% of assets, up from 25% a quarter earlier.

On the sell side, the largest reduction was BioXcel Therapeutics, an estimated $12.5M trimmed.

  • Ikarian Capital's largest Q3 2020 buy was Milestone Pharmaceuticals: 1,743,545 shares worth $12.8M.
  • Ikarian Capital added most to Kiniksa Pharmaceuticals in Q3 2020, an estimated $5.91M increase.
  • Ikarian Capital's biggest Q3 2020 reduction was BioXcel Therapeutics, cutting an estimated $12.5M.
  • Ikarian Capital fully exited Blueprint Medicines in Q3 2020, selling an estimated $15.7M.
  • Ikarian Capital's ten largest holdings make up 41% of its $1.38B portfolio in Q3 2020.
  • Ikarian Capital opened 73 new positions and closed 63 in Q3 2020.
  • Ikarian Capital's portfolio value rose 10% quarter-over-quarter to $1.38B.

Based on Ikarian Capital's 13F filing for Q3 2020, filed 16 Nov 2020.